In December 2023, regulators in the United States approved the first medicine based on CRISPR gene editing, a treatment for sickle cell disease.
Notice: Our site allows paid contributors to share content. Daily monitoring is not always possible. The owner does not support or endorse illegal activities, such as casinos, betting, CBD, or gambling.